报价延迟最少15分钟:2026/02/15 02:49 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.735 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.25/-10.20
|
|
企业价值
2.25M
|
| 资产负债 |
|
每股账面净值
-5.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions. |
